Unique Fourier 80 ‘Multi-Talent’ offers ¹H NMR and choice of 15 X-nuclei with just one click

At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407545969/en/

Novel multinuclear benchtop Fourier 80 ‘Multi-Talent’ with optional sample changer automation

The Fourier 80 ‘Multi-Talent’ system measures or decouples ¹H, and in addition can select one of 15 different X-nuclei to be either observed in X{¹H} experiments, or selected X-nuclei can be decoupled for proton observation in ¹H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments, and importantly also the exquisitely sensitive inverse ¹H observation methods for ¹³C, ¹⁹F or ¹⁵N experiments.

Similarly, the Fourier 80 ‘Multi-Talent’ can observe ¹⁹F{¹H} with proton decoupling for the simplification of ¹⁹F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like ⁷Li, ²³Na, and ¹¹B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.

The ‘Multi-Talent’ uses standard 5 mm NMR samples, includes gradient spectroscopy, with options for adjustable sample temperature (AT), or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.

Dr. Agnes Haber, the Fourier 80 Product Manager at Bruker BioSpin, stated: "The Fourier 80 ‘Multi-Talent’ represents a game-changing advancement in benchtop FT-NMR, with next-generation multinuclear capabilities addressing the demand for a versatile system for ¹H-NMR, plus an unprecedented choice of fifteen X-nuclei, with ease, and even under automation. We have already successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and we anticipate that this novel system may become the new de facto standard in benchtop multinuclear NMR spectroscopy."

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407545969/en/